- CytoDyn (OTCQB:CYDY) has reached enrollment of 293 patients in its Phase 3 trial for COVID-19 patients with severe-to-critical symptoms, thereby meeting requested criteria for a second interim efficacy analysis by the Data Safety Monitoring Committee (DSMC).
- The company expects to enroll the remaining 97 patients in the next few weeks to complete the trial this year (n=390).
- After the first interim analysis, the DSMC requested a second analysis of all data after enrollment had reached 75% of the total patients.
- Approx. five weeks ago, first interim analysis was completed and the trial was recommended to continue without modification.
- The company plans to initiate its Phase 2 COVID-19 long hauler trial and complete enrollment in 4-6 weeks.
- On another front, CytoDyn is also about to enroll its first patient in the NASH trial this month.
- https://seekingalpha.com/news/3638571-cytodyn-reaches-target-enrollment-for-second-interim-analysis-of-phase-3-covidminus-19-trial
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.